Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled TrialShow others and affiliations
2022 (English)In: Nutrients, E-ISSN 2072-6643, Vol. 14, no 19, article id 3998
Article in journal (Refereed) Published
Abstract [en]
Probiotic and omega-3 supplements have been shown to reduce inflammation, and dual supplementation may have synergistic health effects. We investigated if the novel combination of a multi-strain probiotic (containing B. lactis Bi-07, L. paracasei Lpc-37, L. acidophilus NCFM, and B. lactis Bl-04) alongside omega-3 supplements reduces low-grade inflammation as measured by high-sensitivity C-reactive protein (hs-CRP) in elderly participants in a proof-of-concept, randomized, placebo-controlled, parallel study (NCT04126330). In this case, 76 community-dwelling elderly participants (median: 71.0 years; IQR: 68.0-73.8) underwent an intervention with the dual supplement (n = 37) or placebo (n = 39) for eight weeks. In addition to hs-CRP, cytokine levels and intestinal permeability were also assessed at baseline and after the eight-week intervention. No significant difference was seen for hs-CRP between the dual supplement group and placebo. However, interestingly, supplementation did result in significant increases in the level of the anti-inflammatory marker IL-10. In addition, dual supplementation increased levels of valeric acid, further suggesting the potential of the supplements in reducing inflammation and conferring health benefits. Together, the results suggest that probiotic and omega-3 dual supplementation exerts modest effects on inflammation and may have potential use as a non-pharmacological treatment for low-grade inflammation in the elderly.
Place, publisher, year, edition, pages
MDPI, 2022. Vol. 14, no 19, article id 3998
Keywords [en]
RCT, chronic low-grade inflammation, elderly, hs-CRP, n-3 PUFA, omega-3, probiotics, short-chain fatty acids
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-101799DOI: 10.3390/nu14193998ISI: 000866959300001PubMedID: 36235651Scopus ID: 2-s2.0-85139781366OAI: oai:DiVA.org:oru-101799DiVA, id: diva2:1704043
Note
Funding agency:
Pfizer Consumer Healthcare
2022-10-172022-10-172025-02-11Bibliographically approved